BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23523308)

  • 1. MYC-y mice: from tumour initiation to therapeutic targeting of endogenous MYC.
    Morton JP; Sansom OJ
    Mol Oncol; 2013 Apr; 7(2):248-58. PubMed ID: 23523308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
    Kim J; Roh M; Abdulkadir SA
    BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
    Yu D; Thomas-Tikhonenko A
    Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia.
    Mahauad-Fernandez WD; Rakhra K; Felsher DW
    Methods Mol Biol; 2021; 2318():297-312. PubMed ID: 34019298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC in oncogenesis and as a target for cancer therapies.
    Albihn A; Johnsen JI; Henriksson MA
    Adv Cancer Res; 2010; 107():163-224. PubMed ID: 20399964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.
    Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y
    Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
    Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.
    Hoellein A; Fallahi M; Schoeffmann S; Steidle S; Schaub FX; Rudelius M; Laitinen I; Nilsson L; Goga A; Peschel C; Nilsson JA; Cleveland JL; Keller U
    Blood; 2014 Sep; 124(13):2081-90. PubMed ID: 25143484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concepts to Target MYC in Pancreatic Cancer.
    Wirth M; Mahboobi S; Krämer OH; Schneider G
    Mol Cancer Ther; 2016 Aug; 15(8):1792-8. PubMed ID: 27406986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases.
    Sipos F; Firneisz G; Műzes G
    World J Gastroenterol; 2016 Sep; 22(35):7938-50. PubMed ID: 27672289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal cooperation between mutant Hras and c-myc or TGFα in the regulation of mouse hepatocyte growth or transformation in vivo.
    Stein TJ; Bowden M; Sandgren EP
    Liver Int; 2011 Oct; 31(9):1298-305. PubMed ID: 22093452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taking on challenging targets: making MYC druggable.
    Horiuchi D; Anderton B; Goga A
    Am Soc Clin Oncol Educ Book; 2014; ():e497-502. PubMed ID: 24857145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A big step for MYC-targeted therapies.
    Atibalentja DF; Deutzmann A; Felsher DW
    Trends Cancer; 2024 May; 10(5):383-385. PubMed ID: 38580534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long journey to bring a Myc inhibitor to the clinic.
    Whitfield JR; Soucek L
    J Cell Biol; 2021 Aug; 220(8):. PubMed ID: 34160558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression.
    Wang H; Wang P; Xu M; Song X; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
    Cell Death Dis; 2021 Feb; 12(2):200. PubMed ID: 33608500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy.
    Lin CJ; Malina A; Pelletier J
    Cancer Res; 2009 Oct; 69(19):7491-4. PubMed ID: 19773439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis.
    Sluss HK; Gannon H; Coles AH; Shen Q; Eischen CM; Jones SN
    Mol Cancer Res; 2010 Feb; 8(2):216-22. PubMed ID: 20145032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics.
    Chen BJ; Wu YL; Tanaka Y; Zhang W
    Int J Biol Sci; 2014; 10(10):1084-96. PubMed ID: 25332683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
    Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
    Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The many faces of c-MYC.
    Pelengaris S; Khan M
    Arch Biochem Biophys; 2003 Aug; 416(2):129-36. PubMed ID: 12893289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.